Stay updated on NIVO-IPI-TAXANE in Metastatic NSCLC Clinical Trial

Sign up to get notified when there's something new on the NIVO-IPI-TAXANE in Metastatic NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the NIVO-IPI-TAXANE in Metastatic NSCLC Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    6 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, indicating a potential update or modification in the ongoing Phase II clinical trial of combination Nivolumab, Ipilimumab, and Paclitaxel in patients with untreated metastatic non-small cell lung cancer (NSCLC). This change may reflect new data or adjustments in the study protocol related to the safety and efficacy assessment of the treatment combination.
    Difference
    0.1%
    Check dated 2024-06-06T14:37:08.000Z thumbnail image
  7. Check
    21 days ago
    Change Detected
    Summary
    The webpage has been updated to include detailed eligibility criteria for participants, specifying the required health conditions and prior treatments for inclusion in the study. Previously, no information was provided about the participation criteria for collaborators and investigators.
    Difference
    46%
    Check dated 2024-05-22T21:37:30.000Z thumbnail image
  8. Check
    43 days ago
    Change Detected
    Difference
    0.9%
    Check dated 2024-04-30T22:50:52.000Z thumbnail image

Stay in the know with updates to NIVO-IPI-TAXANE in Metastatic NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the NIVO-IPI-TAXANE in Metastatic NSCLC Clinical Trial page.